Jun 25, 2019 8:30 am EDT World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
Jun 5, 2019 8:30 am EDT SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
May 30, 2019 8:30 am EDT SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
May 8, 2019 4:15 pm EDT SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update
May 6, 2019 8:30 am EDT SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
May 1, 2019 8:30 am EDT SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Apr 15, 2019 8:30 am EDT SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call
Apr 8, 2019 8:15 am EDT SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
Apr 3, 2019 8:30 am EDT SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
